<?xml version="1.0" encoding="UTF-8"?>
<p id="Par14">Forty-eight patients received forodesine (4 in phase 1, 44 in phase 2) (Fig. 
 <xref rid="Fig1" ref-type="fig">1</xref>). Overall, the most common reasons for discontinuation were PD (
 <italic>n</italic> = 35) and AEs (
 <italic>n</italic> = 8). The study cohort had a median age of 69.5 years (range, 32–79 years) and had received a median of two prior treatment regimens (range, 1–9); most had PTCL-NOS (46%) or AITL (40%) (Table 
 <xref rid="Tab1" ref-type="table">1</xref>).
</p>
